Skip to main content
Erschienen in: Rheumatology International 6/2020

22.01.2020 | Case Based Review

Systemic sclerosis in mother and daughter with susceptible HLA haplotype and anti-topoisomerase I autoantibodies

verfasst von: Ekaterina Krasimirova Kurteva, Vladimira Vasileva Boyadzhieva, Nikolay Rumenov Stoilov

Erschienen in: Rheumatology International | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis is a rare systemic autoimmune rheumatic disease which is thought to be polygenic disorder contributed by both genetic and environmental factors. A positive family history of SSc is the strongest risk factor yet identified for SSc; however, the absolute risk for each family member remains quite low. A systematic literature search was performed in MEDLINE and Scopus database for studies published only in English that investigated the prevalence of SSc in first-degree relatives of SSc patients and whether SSc family members have greater frequency of I autoantibodies (ATA) than expected. Following keywords and terms: “systemic sclerosis”, “scleroderma”, “familial”,“ATA”, “topoisomerase”, and “anti-Scl70” were used to select the appropriate articles. From the 21 initially identified articles, 16 were eliminated because of the inclusion criteria, and five articles concerning familial occurrence of SSc in first-degree relatives positive for ATA were included for further analysis. Two case reports were described—a daughter and a mother diagnosed with systemic sclerosis with ATA tested for specific genotype. In both cases, patients had antinuclear autoantibodies (ANA) at a titer of > 1:1280, AC-29 cell pattern according to ICAP, and their sera were positive for ATA. In addition, anti-SSA/Ro60 autoantibodies were found in the case of the mother. Complementary to ATA positivity, the daughter was also positive for AMA-M2 autoantibodies. The results showed that our patients shared HLA-DRB1*1104-DQA1*0501-DQB1*0301 haplotype and had positive ATA, which corresponds to the strong association between ATA in white subjects and HLA-DRB1*1104, DQA1*0501, DQB1*0301 haplotype (OR = 6.93). Our patients not only shared a risky HLA haplotype for SSc but also manifested with a similar immunological activity, given that they were both positive for ATA. Although infrequent, ATA-positive SSc patients could develop scleroderma renal crisis, as in the case of the mother. Therefore, careful monitoring of the renal function is the best strategy for the case of the daughter. A positive family history is an important hint for patients suspected of autoimmune disease. The cases of familial SSc are quite rare, but they give us the opportunity to compare the genetic background, environmental risk factors, SSc phenotype, ANA type, and prevention of the complications in the course of the disease.
Literatur
1.
Zurück zum Zitat Bolster MB, Silver RM (2015) Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Ed) Rheumatology, 6th ed. Elsevier, Philadelphia, pp 1165–1176 Bolster MB, Silver RM (2015) Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Ed) Rheumatology, 6th ed. Elsevier, Philadelphia, pp 1165–1176
5.
Zurück zum Zitat Englert H, Small-McMahon J, Chambers P, O’Connor H, Davis K, Manolios N et al (1999) Familial risk estimation in systemic sclerosis. Aust N Z J Med 29:36–41CrossRef Englert H, Small-McMahon J, Chambers P, O’Connor H, Davis K, Manolios N et al (1999) Familial risk estimation in systemic sclerosis. Aust N Z J Med 29:36–41CrossRef
8.
Zurück zum Zitat van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 65: 2737–2747. https://doi.org/10.1002/art.38098 van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 65: 2737–2747. https://​doi.​org/​10.​1002/​art.​38098
9.
Zurück zum Zitat Douvas AS, Achten M, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254(20):10514–10522PubMed Douvas AS, Achten M, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254(20):10514–10522PubMed
10.
Zurück zum Zitat Shero JH, Bordwell B, Rothfield NF, Earnshaw WC (1986) Autoantibodies to topoisomerase I are found in sera from scleroderma patients. Science 231:737–740CrossRef Shero JH, Bordwell B, Rothfield NF, Earnshaw WC (1986) Autoantibodies to topoisomerase I are found in sera from scleroderma patients. Science 231:737–740CrossRef
11.
18.
Zurück zum Zitat Molta CT, Khan MA, Aponte CJ, Reynolds TL, Macintyre SS (1989) Familial occurence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: Report of two kindreds with study of HLA antigens and review of the literature. Clin Exp Rheumatol 7:229–236PubMed Molta CT, Khan MA, Aponte CJ, Reynolds TL, Macintyre SS (1989) Familial occurence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: Report of two kindreds with study of HLA antigens and review of the literature. Clin Exp Rheumatol 7:229–236PubMed
26.
30.
Zurück zum Zitat Harvey G, Black C, Maddison P, McHugh NJ (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24(3):477–484PubMed Harvey G, Black C, Maddison P, McHugh NJ (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24(3):477–484PubMed
31.
Zurück zum Zitat Whyte J, Artlett C, Harvey G, Stephens CO, Welsh K, Black C, Maddison PJ, McHugh NJ, United Kingdom Systemic Sclerosis Study Group (1994) HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. J Autoimmun 7(4):509–520 Whyte J, Artlett C, Harvey G, Stephens CO, Welsh K, Black C, Maddison PJ, McHugh NJ, United Kingdom Systemic Sclerosis Study Group (1994) HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. J Autoimmun 7(4):509–520
32.
Zurück zum Zitat Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody. Arthritis Rheum 56(8):2740–2746. https://doi.org/10.1002/art.22747 CrossRefPubMed Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody. Arthritis Rheum 56(8):2740–2746. https://​doi.​org/​10.​1002/​art.​22747 CrossRefPubMed
33.
Zurück zum Zitat Antonioli C, Franceschini F, Cavazzana I, Airò P, Danieli E, Bettoni R, Cattaneo R (2002) Anti-Ro/SSA antibodies in systemic sclerosis (SSc): determination of the fine specificity, clinical and laboratory correlations. Arthritis Res 4(Suppl 1):81. https://doi.org/10.1186/ar527 Antonioli C, Franceschini F, Cavazzana I, Airò P, Danieli E, Bettoni R, Cattaneo R (2002) Anti-Ro/SSA antibodies in systemic sclerosis (SSc): determination of the fine specificity, clinical and laboratory correlations. Arthritis Res 4(Suppl 1):81. https://​doi.​org/​10.​1186/​ar527
Metadaten
Titel
Systemic sclerosis in mother and daughter with susceptible HLA haplotype and anti-topoisomerase I autoantibodies
verfasst von
Ekaterina Krasimirova Kurteva
Vladimira Vasileva Boyadzhieva
Nikolay Rumenov Stoilov
Publikationsdatum
22.01.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 6/2020
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04516-5

Weitere Artikel der Ausgabe 6/2020

Rheumatology International 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.